A Randomized, Open-Label Study of Oral CEP-701 [lestaurtinib] Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations.

Trial Profile

A Randomized, Open-Label Study of Oral CEP-701 [lestaurtinib] Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2016

At a glance

  • Drugs Lestaurtinib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top